Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs CRSP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRSP Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–3 Matrix Metrics)

CRSP Overall Winner 6-Pillar Tally: NTLA 3 – 3 CRSP Matrix Metrics: NTLA 3 – 6 CRSP

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas CRSP carries 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -826.0% operating margin) and revenue trajectory (+1325.1% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs CRSP
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
CRSP NASDAQ Head-to-Head Winner
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80

6-Pillar Scorecard Institutional Category Breakdown (NTLA 3 – 3 CRSP)

Columns: Metric · NTLA · CRSP
1. Valuation Multiples CRSP
Forward P/E N/M 23.4x
Trailing P/E N/M 23.4x
PEG Ratio N/M N/M
EV / Revenue 29.1x N/M
2. Growth & Scale CRSP
Revenue Growth (YoY) -48.0% +1325.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $25M
Market Cap $1.5B $4.1B
3. Profitability & Quality NTLA
Gross Margin N/A N/A
Operating Margin -826.0% -2058.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.6% -25.6%
4. Balance Sheet & Cash Flow NTLA
Cash Generation (TTM) -$358M -$378M
Cash Flow Margin N/A N/A
Net Cash / Leverage $74M Net Debt (0.38x D/E) $588M Net Debt (0.47x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRSP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 101.3% (78th %ile) 97.8% (52nd %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 0.65x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (3) vs CRSP (6)
Institutional Metric NTLA CRSP Criterion Row Edge
Market Capitalization
Scale
$1.5B $4.1B Larger Scale CRSP
Trailing P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Forward P/E Ratio
Valuation
N/M 23.4x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
-48.0% +1325.1% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-826.0% -2058.6% Higher Margin NTLA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.6% -25.6% Higher ROE CRSP
52-Week Range Position
Momentum
20% ($8–$18) 1% ($40–$63) Stronger Trend NTLA
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 1.85β · 60% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 48.6 / 100 (HOLD) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $25M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$378M ($588M Net Debt (0.47x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +5.11 pp
NTLA: -12.43% · CRSP: -17.54%
3M Horizon NTLA +9.54 pp
NTLA: -13.79% · CRSP: -23.33%
6M Horizon CRSP +4.83 pp
NTLA: -21.2% · CRSP: -16.37%
1Y Horizon NTLA +35.88 pp
NTLA: +15.34% · CRSP: -20.54%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue CRSP Revenue NTLA Op. Margin CRSP Op. Margin Margin Leader
FY2018 $30M $0M -298.6% -5087.8% NTLA
FY2019 $40M $290M -246.8% 16.1% CRSP
FY2020 $60M $0M -235.5% -49295.5% NTLA
FY2021 $30M $910M -810.4% 40.8% CRSP
FY2022 $50M $0M -879.0% -56190.4% NTLA
FY2023 $40M $370M -1420.5% -60.0% CRSP
FY2024 $60M $40M -923.1% -1250.4% NTLA
FY2025 $70M $0M -651.7% -18933.6% NTLA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs CRSP Key Questions & Quantitative Answers

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas CRSP carries 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (49.9/100 HOLD vs. CRSP 48.6/100 HOLD), CRSP captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-2058.6% vs. -826.0% operating margin) and revenue trajectory (+1325.1% vs. -48.0% YoY). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile CRSP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with CRSP at +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while CRSP shifted -86.2%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRSP.

CRSP screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus CRSP (-25.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.